Статья

A heterologous virus-vectored vaccine for prevention of middle east respiratory syndrome induces long protective immune response against MERS-cov

A. Kovyrshina, I. Dolzhikova, D. Grousova, M. Balyasin, A. Botikov, L. Panina, I. Gordeychuk, S. Gulyaev, O. Zubkova, T. Ozharovskaya, O. Popova, A. Tukhvatulin, E. Tokarskaya, Y. Simakova, I. Esmagambetov, D. Shcheblyakov, I. Evgrafova, P. Deryabin, S. Borisevich, B. Naroditsky, D. Logunov, A. Gintsburg,
2020

Introduction. Middle East respiratory syndrome (MERS) is acute inflammatory disease of respiratory system with a high mortality, caused by coronavirus MERS-CoV. At present moment, we still lack specific therapeutic preparations and vaccines against MERS. Vaccine administration can help to limit the spread of the disease and lower the mortality. Duration of vaccine-induced immune response is one of the key characteristics of a vaccine, which is connected with duration of its protective effectiveness. Unfortunately, the data on duration of vaccine-induced immune response against MERS is scarce. The aim of the study was to determine duration of humoral immune response in mice and primates and duration of protective immune response in mice after immunization with the heterologous virus-vectored vaccine against MERS (BVRS-GamVac-Combi), developed earlier by our research group. Material and methods. To study duration of humoral immune response, we used mice of C57BL/6 strain and common marmosets. Animals were immunized with the vaccine BVRSGamVac-Combi, based on recombinant adenoviral vectors rAd26 and rAd5. Antigen-specific-antibody titers were determined with ELISA, virus-neutralizing antibody titers were measured with virus neutralization assay using MERS-CoV (EMC/2012). To study duration of protective immune response, we used a model of lethal infection on transgenic mice, carrying human DPP4 gene of viral receptor. Results. In present research, we showed that vaccination of animals with BVRS-GamVac-Combi induced robust humoral immune response, which persisted at least 18 months after immunization. In addition, our vaccine protected 100 % of animals from lethal infection for at least 7 months after immunization. Conclusion. Strength of vaccine-induced immune response is generally connected with a protective effectiveness of a vaccine. One of the key problems of vaccine design is to find a way to provide as long and robust immune response as possible. Duration of vaccine-induced immune response is one of the key characteristics of a vaccine, which demands quality control during multiple steps of a vaccine development.

Цитирование

Похожие публикации

Источник

Версии

  • 1. Version of Record от 2020-01-01

Метаданные

Об авторах
  • A. Kovyrshina
    Ministry of Health of Russian Federation
  • I. Dolzhikova
    Ministry of Health of Russian Federation
  • D. Grousova
    Ministry of Health of Russian Federation
  • M. Balyasin
    Ministry of Health of Russian Federation
  • A. Botikov
    Ministry of Health of Russian Federation
  • L. Panina
    Ministry of Health of Russian Federation
  • I. Gordeychuk
    Ministry of Health of Russian Federation, Sechenov First Moscow State Medical University, Russian Academy of Sciences
  • S. Gulyaev
    Russian Academy of Sciences
  • O. Zubkova
    Ministry of Health of Russian Federation
  • T. Ozharovskaya
    Ministry of Health of Russian Federation
  • O. Popova
    Ministry of Health of Russian Federation
  • A. Tukhvatulin
    Ministry of Health of Russian Federation
  • E. Tokarskaya
    Ministry of Health of Russian Federation
  • Y. Simakova
    Ministry of Health of Russian Federation
  • I. Esmagambetov
    Ministry of Health of Russian Federation
  • D. Shcheblyakov
    Ministry of Health of Russian Federation
  • I. Evgrafova
    Ministry of Health of Russian Federation
  • P. Deryabin
    Ministry of Health of Russian Federation
  • S. Borisevich
    Russian Federation Ministry of Defence
  • B. Naroditsky
    Ministry of Health of Russian Federation, Sechenov First Moscow State Medical University
  • D. Logunov
    Ministry of Health of Russian Federation
  • A. Gintsburg
    Ministry of Health of Russian Federation, Sechenov First Moscow State Medical University
Название журнала
  • Immunologiya
Том
  • 41
Выпуск
  • 2
Страницы
  • 135-143
Номер гранта
  • undefined
Тип документа
  • journal article
Тип лицензии Creative Commons
  • CC BY
Правовой статус документа
  • Свободная лицензия
Источник
  • scopus